RAGE (receptor)

AGER
Available structures
PDB	Ortholog search: PDBe RCSB
List of PDB id codes
	2ENS, 2M1K, 2LE9, 4LP5, 2MOV, 3O3U, 2LMB, 4LP4, 4OF5, 4OI8, 4XYN, 2MJW, 2E5E, 2L7U, 3CJJ, 4OFV, 4P2Y, 4OI7, 4YBH,%%s1PWI, 2BJP, 2E5E, 2ENS, 2L7U, 2LE9, 2LMB, 2M1K, 2MJW, 2MOV, 3CJJ, 3O3U, 4LP4, 4LP5, 4OF5, 4OFV, 4OI7, 4OI8, 4P2Y, 4XYN
Identifiers
Aliases	AGER, Ager, RAGE, SCARJ1, advanced glycosylation end product-specific receptor, advanced glycosylation end-product specific receptor, sRAGE
External IDs	OMIM: 600214; MGI: 893592; HomoloGene: 883; GeneCards: AGER; OMA:AGER - orthologs
Gene location (Human)
Chr.	Chromosome 6 (human)
End	32,184,322 bp
Gene location (Mouse)
Chr.	Chromosome 17 (mouse)
End	34,819,910 bp
RNA expression pattern
	Top expressed in
	right lung; ; upper lobe of left lung; ; right lobe of thyroid gland; ; left lobe of thyroid gland; ; granulocyte; ; spleen; ; blood; ; right uterine tube; ; gastric mucosa; ; lymph node;
	Top expressed in
	right lung lobe; ; left lung; ; left lung lobe; ; granulocyte; ; thyroid gland; ; trachea; ; morula; ; renal corpuscle; ; external carotid artery; ; renal pelvis;
	More reference expression data
	n/a
Gene ontology
Molecular function	S100 protein binding; protein binding; identical protein binding; transmembrane signaling receptor activity; advanced glycation end-product binding; heparin binding; amyloid-beta binding; scavenger receptor activity; signaling receptor activity; advanced glycation end-product receptor activity; protein-containing complex binding;
Cellular component	integral component of membrane; membrane; integral component of plasma membrane; extracellular region; fibrillar center; plasma membrane; cell junction; cell surface; apical plasma membrane; postsynapse;
Biological process	negative regulation of interleukin-10 production; positive regulation of interleukin-12 production; cell surface receptor signaling pathway; response to wounding; positive regulation of NF-kappaB transcription factor activity; positive regulation of dendritic cell differentiation; innate immune response; inflammatory response; regulation of T cell mediated cytotoxicity; regulation of CD4-positive, alpha-beta T cell activation; positive regulation of activated T cell proliferation; negative regulation of advanced glycation end-product receptor activity; protein localization to membrane; positive regulation of JUN kinase activity; regulation of DNA binding; induction of positive chemotaxis; regulation of inflammatory response; response to hypoxia; astrocyte development; neuron projection development; negative regulation of connective tissue replacement involved in inflammatory response wound healing; positive regulation of monocyte chemotactic protein-1 production; positive regulation of protein phosphorylation; receptor-mediated endocytosis; learning or memory; glucose mediated signaling pathway; positive regulation of heterotypic cell-cell adhesion; transcytosis; positive regulation of JNK cascade; regulation of synaptic plasticity; positive regulation of astrocyte activation; positive regulation of ERK1 and ERK2 cascade; regulation of spontaneous synaptic transmission; regulation of long-term synaptic potentiation; negative regulation of long-term synaptic potentiation; negative regulation of long-term synaptic depression; regulation of p38MAPK cascade; positive regulation of p38MAPK cascade; regulation of NIK/NF-kappaB signaling; positive regulation of NIK/NF-kappaB signaling; positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process; negative regulation of blood circulation; positive regulation of microglial cell activation; response to amyloid-beta; cellular response to amyloid-beta; positive regulation of monocyte extravasation; endocytosis;
	Sources:Amigo / QuickGO
Orthologs
	177
	11596
ENSG00000237405; ENSG00000206320; ENSG00000231268; ENSG00000234729; ENSG00000229058;
	ENSG00000204305; ENSG00000230514
	ENSMUSG00000015452
	Q15109
	Q62151
NM_001136; NM_001206929; NM_001206932; NM_001206934; NM_001206936;
	NM_001206940; NM_001206954; NM_001206966; NM_172197
	NM_001271422; NM_001271423; NM_001271424; NM_007425
NP_001127; NP_001193858; NP_001193861; NP_001193863; NP_001193865;
	NP_001193869; NP_001193883; NP_001193895; NP_751947
	NP_001258351; NP_001258352; NP_001258353; NP_031451
	Wikidata
View/Edit Human	View/Edit Mouse

RAGE (receptor for advanced glycation end-products), also called AGER, is a 35 kilodalton transmembrane receptor of the immunoglobulin super family which was first characterized in 1992 by Neeper et al. Its name comes from its ability to bind advanced glycation end-products (AGEs), which include chiefly glycoproteins, the glycans of which have been modified non-enzymatically through the Maillard reaction. In view of its inflammatory function in innate immunity and its ability to detect a class of ligands through a common structural motif, RAGE is often referred to as a pattern recognition receptor. RAGE also has at least one other agonistic ligand: high mobility group protein B1 (HMGB1). HMGB1 is an intracellular DNA-binding protein important in chromatin remodeling which can be released by necrotic cells passively, and by active secretion from macrophages, natural killer cells, and dendritic cells.

The interaction between RAGE and its ligands is thought to result in pro-inflammatory gene activation. Due to an enhanced level of RAGE ligands in diabetes or other chronic disorders, this receptor is hypothesised to have a causative effect in a range of inflammatory diseases such as diabetic complications, Alzheimer's disease and even some tumors.

Isoforms of the RAGE protein, which lack the transmembrane and the signaling domain (commonly referred to as soluble RAGE or sRAGE) are hypothesized to counteract the detrimental action of the full-length receptor and are hoped to provide a means to develop a cure against RAGE-associated diseases.